Last updated: 2026-10-17 02:22:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Damora Therapeutics, Inc. (DMRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.47, with a market capitalization of $1.14B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.50 to $34.89. This page covers its latest market performance, valuation, price trends and company information.
$1.14B | |
$18.69 | |
$34.89 | |
$16.50 | |
$18.74 | |
757.06K | |
524.19K | |
-- | |
$34.89 | |
$16.50 | |
-- | |
-- |
Damora Therapeutics, Inc. (DMRA) last closed at $18.74 as of 2026-10-16 23:31:00, unchanged from the previous close of $18.74.
During the latest regular trading session, DMRA traded between $16.50 and $34.89, with a volume of 757.06K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Damora Therapeutics, Inc. (DMRA) moved from $20.24 to $18.47, representing a decline of 8.73% ($1.77).
The stock traded between $17.48 and $21.86 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 341.12 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10.7%
DMRA is currently trading at $18.47, placing it 10.7% of the way from its 52-week low of $16.50 to its 52-week high of $34.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Damora Therapeutics, Inc. (DMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.